XTNT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

30.75M

-2.42%

-0.005

-87.5%

28.50M

-13.38%

-0.005

-75%

Estimates Revision

The market is revising Upward the revenue expectations for Xtant Medical Holdings, Inc. (XTNT) for FY2025, with the revenue forecasts being adjusted by 2.7% over the past three months. During the same period, the stock price has changed by 15.73%.

Revenue Estimates for FY2025

Revise Upward

+2.7%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+25%

In Past 3 Month

Stock Price

Go Up

+15.73%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.750

Low

1.50

Averages

1.50

High

1.50

Current: 0.750

Low

1.50

Averages

1.50

High

1.50

BTIG

Buy

downgrade

2025-11-11

Reason

BTIG

Price Target

2025-11-11

downgrade

Buy

Reason

BTIG lowered the firm's price target on Xtant Medical to $1.50 from $2 and keeps a Buy rating on the shares. Xtant Medical reported Q3 revenue up 19% year over year and EPS of 1c, slightly above estimates, driven by $5.5M in license revenue, the analyst tells investors in a research note. The company reaffirmed FY25 guidance of $131M-$135M and appears positioned for self-sustained growth, with high single-digit expansion expected in FY26 and beyond, BTIG says.

Valuation Metrics

The current forward P/E ratio for Xtant Medical Holdings Inc (XTNT.A) is -140.66, compared to its 5-year average forward P/E of -13.04. For a more detailed relative valuation and DCF analysis to assess Xtant Medical Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.04

Current PE

-140.66

Overvalued PE

19.42

Undervalued PE

-45.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

21.27

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

41.60

Undervalued EV/EBITDA

0.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.03

Current PS

0.00

Overvalued PS

1.73

Undervalued PS

0.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XTNT News & Events

Events Timeline

No data

News

5.0

12-11PRnewswire

Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft

8.5

12-01Businesswire

Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach

7.5

12-01Newsfilter

Xtant Medical Sells Non-Core Assets for $19.2 Million

People Also Watch

Frequently Asked Questions

What is Xtant Medical Holdings Inc (XTNT) stock price today?

The current price of XTNT is 0.7499 USD — it has increased 7.14 % in the last trading day.

What is Xtant Medical Holdings Inc (XTNT)'s business?

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

What is the price predicton of XTNT Stock?

What is Xtant Medical Holdings Inc (XTNT)'s revenue for the last quarter?

Xtant Medical Holdings Inc revenue for the last quarter amounts to 33.26M USD, increased 19.04 % YoY.

What is Xtant Medical Holdings Inc (XTNT)'s earnings per share (EPS) for the last quarter?

Xtant Medical Holdings Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

What changes have occurred in the market's expectations for Xtant Medical Holdings Inc (XTNT)'s fundamentals?

How many employees does Xtant Medical Holdings Inc (XTNT). have?

Xtant Medical Holdings Inc (XTNT) has 217 emplpoyees as of December 16 2025.

What is Xtant Medical Holdings Inc (XTNT) market cap?

Today XTNT has the market capitalization of 98.00M USD.